Compare Crocs, Inc. (CROX) vs Oscar Health Inc (OSCR) Price & Performance

Crocs (CROX) trades at $116.84, down 2.81% today, amid bearish technical signals but strong fundamental valuation metrics. The stock shows attractive P/E of 10.23 and P/S of 1.46, with robust profitability margins including 57.47% gross margin and 42.3% ROE. Recent earnings have consistently beaten expectations, with Q2 2026 EPS of $4.55 surpassing the $4.35 estimate. The company maintains strong cash flow generation despite a net loss in 2025, with management focusing on product innovation and HEYDUDE brand repositioning.

CROX presents a compelling value opportunity with discounted valuation multiples relative to historical performance, though near-term technical weakness and competitive pressures warrant caution. Analyst consensus remains bullish with $136.78 price target representing 17% upside potential. Key risks include consumer discretionary spending sensitivity and execution challenges with brand diversification initiatives. The stock's current levels offer entry points for long-term investors seeking exposure to a profitable footwear company with strong brand recognition.

Oscar Health (OSCR) trades at $32.91, up 1.76% with strong technical momentum and bullish moving average signals. The company shows impressive revenue growth from $11.7B in 2025 to $15.3B in 2026, with profitability turning positive at $551M net income. Recent earnings beats and raised guidance have driven positive sentiment, though the stock faces challenges from rising medical costs and competitive pressures in the ACA market.

The outlook remains constructive with analyst consensus at $34.00 and strong institutional interest, though investors should monitor execution risks and medical cost trends. The combination of market share gains, margin expansion potential, and bullish technical setup supports further upside if the company can maintain its growth trajectory.